Supernus Pharmaceuticals Inc (SUPN) is now in the Undervalued zone, suggesting that its current forward PE ratio of 19.24 is considered Undervalued compared with the five-year average of 21.43. The fair price of Supernus Pharmaceuticals Inc (SUPN) is between 69.29 to 96.42 according to relative valuation method. Compared to the current price of 55.09 USD , Supernus Pharmaceuticals Inc By Undervalued By 20.49%.

Relative Value

Fair Zone

69.29-96.42

Current Price：55.09

20.49%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Supernus Pharmaceuticals Inc (SUPN) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Supernus Pharmaceuticals Inc (SUPN) has a current Price-to-Book (P/B) ratio of 2.69. Compared to its 3-year average P/B ratio of 1.94, the current P/B ratio is approximately 39.00% higher. Relative to its 5-year average P/B ratio of 1.98, the current P/B ratio is about 36.07% higher. Supernus Pharmaceuticals Inc (SUPN) has a Forward Free Cash Flow (FCF) yield of approximately 2.49%. Compared to its 3-year average FCF yield of 7.07%, the current FCF yield is approximately -64.73% lower. Relative to its 5-year average FCF yield of 7.26%, the current FCF yield is about -65.64% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for SUPN competitors is 13.67, providing a benchmark for relative valuation. Supernus Pharmaceuticals Inc Corp (SUPN.O) exhibits a P/S ratio of 3.46, which is -74.72% above the industry average. Given its robust revenue growth of 21.48%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of SUPN increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of SUPN in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is SUPN currently overvalued or undervalued?

Supernus Pharmaceuticals Inc (SUPN) is now in the Undervalued zone, suggesting that its current forward PE ratio of 19.24 is considered Undervalued compared with the five-year average of 21.43. The fair price of Supernus Pharmaceuticals Inc (SUPN) is between 69.29 to 96.42 according to relative valuation method. Compared to the current price of 55.09 USD, Supernus Pharmaceuticals Inc is Undervalued By 20.49%.

What is Supernus Pharmaceuticals Inc (SUPN) fair value?

SUPN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Supernus Pharmaceuticals Inc (SUPN) is between 69.29 to 96.42 according to relative valuation method.

How does SUPN's valuation metrics compare to the industry average?

The average P/S ratio for SUPN's competitors is 13.67, providing a benchmark for relative valuation. Supernus Pharmaceuticals Inc Corp (SUPN) exhibits a P/S ratio of 3.46, which is -74.72% above the industry average. Given its robust revenue growth of 21.48%, this premium appears sustainable.

What is the current P/B ratio for Supernus Pharmaceuticals Inc (SUPN) as of Mar 03 2026?

As of Mar 03 2026, Supernus Pharmaceuticals Inc (SUPN) has a P/B ratio of 2.69. This indicates that the market values SUPN at 2.69 times its book value.

What is the current FCF Yield for Supernus Pharmaceuticals Inc (SUPN) as of Mar 03 2026?

As of Mar 03 2026, Supernus Pharmaceuticals Inc (SUPN) has a FCF Yield of 2.49%. This means that for every dollar of Supernus Pharmaceuticals Inc's market capitalization, the company generates 2.49 cents in free cash flow.

What is the current Forward P/E ratio for Supernus Pharmaceuticals Inc (SUPN) as of Mar 03 2026?

As of Mar 03 2026, Supernus Pharmaceuticals Inc (SUPN) has a Forward P/E ratio of 19.24. This means the market is willing to pay $19.24 for every dollar of Supernus Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Supernus Pharmaceuticals Inc (SUPN) as of Mar 03 2026?

As of Mar 03 2026, Supernus Pharmaceuticals Inc (SUPN) has a Forward P/S ratio of 3.46. This means the market is valuing SUPN at $3.46 for every dollar of expected revenue over the next 12 months.

SUPN Valuation